A unique case of very low‐dose subcutaneous ketamine use: Maintenance option of ketamine for treatment‐resistant depression
Adem T. Can, Daniel F. Hermens, Jim Lagopoulos
Clinical Case Reports December 1, 2022 DOI: 10.1002/ccr3.6675
Summary
AI-generated from the abstractA single patient with severe treatment-resistant depression received maintenance therapy with very low-dose subcutaneous ketamine, following initial improvement with intravenous ketamine. A retrospective chart review showed that this approach sustained the antidepressant response without significant side effects, suggesting a potential alternative maintenance strategy for patients who respond to intravenous ketamine but require ongoing treatment.
Study at a glance
| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | Patient with severe treatment-resistant depression |
| Intervention | subcutaneous ketamine |
| Dose | very low-dose |
| Citations | 6 |
| Key finding | Very low-dose subcutaneous ketamine maintenance therapy sustained antidepressant response in a patient with severe treatment-resistant depression. |
Abstract
Abstract Numerous studies have demonstrated that low‐dose subanesthetic intravenous ketamine infusion treatment leads to rapid improvement of treatment‐resistant depression. The following case report describes the use of a very low‐dose subcutaneous ketamine as a form of maintenance in a patient with severe treatment‐resistant depression using a retrospective chart review.